BOVILIS® NASALGEN®
Bovine Rhinotracheitis-Parainfluenza 3-Respiratory Syncytial Virus Vaccine
Product Description
The color of longer IBR protection.
BOVILIS® NASALGEN® 3 offers young calves an unrivaled BRD defense. With 195 days of IBR protection plus BRSV and PI3, BOVILIS NASALGEN 3 is the insurance you need to give your young calves the strong foundation they deserve. And with a unique BluShadow®, there’s no second guessing which animals have been vaccinated.
Indications
This product has been shown to be effective for the vaccination of healthy cattle, 1 week of age or older against infectious bovine rhinotracheitis (IBR) virus, bovine respiratory syncytial virus (BRSV) and parainfluenza 3 virus (PI3). Duration of immunity against IBR is at least 195 days, against BRSV is at least 78 days, and against PI3 is at least 95 days.
Diseases
- Infectious bovine rhinotracheitis (IBR)
- Bovine respiratory syncytial virus (BRSV)
- Parainfluenze 3 (PI3)
Key Benefits
- Designed with IBR strains that are not temperature-sensitive.1 Ensures the vaccine will replicate and protect in any situation.
- Unique BluShadow® diluent for confident administration.
- Proven safe in pregnant cows and in calves nursing pregnant cows.
Long-lasting Duration of Immunity
- 195 days against IBR
- 95 days against PI3
- 78 days against BRSV
A Game-changing Vaccine
nnovation is critical in vaccine development. For decades it was believed that vaccinating young animals was not effective because of maternal antibody interference. The industry needed to find a way to protect young calves from BRD.
Learn from members of the team who brought to market BOVILIS NASALGEN 3-PMH — the first and only intranasal BRD vaccine offering protection against viral and bacterial pathogens.
Dosage
Shake well and administer a 2 mL dose by the intranasal route. For advice on revaccination frequency, contact your veterinarian.
Supplied
20 mL x 10 doses (2 mL per dose)
25 mL x 1 dose/2 mL x 25 doses (2mL per dose)
100 mL x 50 doses (2 mL per dose)
Caution
Store at 2 to 8°C (35 to 46°F). Fetal health risks associated with the vaccination of pregnant animals with this vaccine cannot be unequivocally determined during clinical trials conducted for licensure. Appropriate strategies to address the risks associated with vaccine use in pregnant animals should be discussed with a veterinarian. Use entire contents when first opened. Do not use chemical disinfectants to sterilize syringes or needles. Do not mix with other products, except as specified on the label. Inactivate unused contents before disposal. Do not vaccinate within 21 days of slaughter. Anaphylactoid reactions may occur following use. Antidote: Epinephrine. Contains Penicillin and Streptomycin as a preservative. In case of human exposure, contact a physician.
FOR ANIMAL USE ONLY.
Research
Contact
U.S. only: Merck Animal Health livestocktechsrvc@merck-animal-health.com or call 1-800-211-3573
For more information regarding efficacy and safety data, go to productdata.aphis.usda.gov
For additional information, please see the product label.
References
- Grissett GP, et al. Effect of Ambient Temperature on Viral Replication and Serum Antibody Titers Following Administration of a Commercial Intranasal Modified-Live Infectious Bovine Rhinotracheitis-Parainfluenza-3 Virus Vaccine to Beef Cattle Housed in High- and Moderate-Ambient Temperature Environments. Am J Vet Res. 2014;75(12):1076-1082.
Go To United States
Algeria
Argentina
Australia
Austria
Bahrain
Belgium (Dutch)
Brazil
Canada (English)
Chile
Colombia
Croatia
Czech Republic
Denmark
Ecuador
Egypt
Finland
France
Germany
Greece
Hungary
India
Indonesia
Iraq
Ireland
Israel
Italy
Japan
Jordan
Kuwait
Lebanon
Malaysia
Mexico
Morocco
Netherlands
New Zealand
Norway
Oman
Panama
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russian Federation
Saudi Arabia
South Africa
South Korea
Spain
Sweden
Switzerland (French)
Taiwan
Thailand
Tunisia
Turkey
Ukraine
United Arab Emirates
United Kingdom
Uruguay
Yemen
Global